key: cord-263552-6qhb02l2 authors: Chokroverty, Sudhansu title: The Many Faces and Fangs of COVID-19: An Editorial date: 2020-06-05 journal: Sleep Med DOI: 10.1016/j.sleep.2020.06.006 sha: doc_id: 263552 cord_uid: 6qhb02l2 nan affecting the USA and Europe. According to the WHO, as of June 1 st 2020 COVID-19 has 24 affected over six million (6,057,853) people worldwide, killing over 370,000 (371,166) including 25 over one million (1, 734, 040) Much about this novel virus currently remains unknown, including i. the nature of its invasion of 29 the human mind and body; ii. its pathophysiological mechanism; iii. the long-term natural history 30 of COVID-19; and iv. the burden of the disease involving multiple organs [2] [3] [4] . The clinical 31 spectrum is still evolving [5] [6] [7] [8] [9] [10] [11] [12] . We do know it severely affects the vulnerable elderly 32 population and those with significant comorbidities with high mortality. Children may develop 33 pediatric multisystem inflammatory syndrome resembling Kawasaki disease (a rare condition 34 also known as mucocutaneous lymph node syndrome) which may be a rare complication of 35 picture is still evolving), stroke, mostly thrombosis of large vessel in relatively young people 122 [16], but could be thromboembolic and microangiopathic affecting small vessels, cerebellar 123 ataxia, altered state of consciousness and impaired vigilance, confusion and delirium, as well as 124 visual loss and seizures [21, 22] . The PNS manifestations may include Guillain-Barre-like 125 syndrome, other neuromuscular disorders (eg, diffuse myalgia or possibly polymyositis and 126 neurogenic pain) [21, 22] . No [20] . Although ACE-R2 is thought to be a co-receptor for entry of 146 coronavirus into the human body, the joint recommendation decision by the American 147 College of Cardiology and the American Heart Association is to continue taking these 148 medications as prescribed until sufficient evidence is available [20] . 149 Only time will tell whether we will defeat this malignant viral epidemic. Indeed, we have a 150 herculean task ahead of us. What is needed desperately now is an effective vaccine as a 151 prophylaxis to prevent future occurrence as well as an effective treatment. We are making valiant 152 progress in both directions but we are not there yet. Perhaps we will succeed in those endeavors 153 in the early or middle part of the next year (2021). For the sake of our health, humanity, and 154 economy we continue to hope for good news. In the meantime, we must follow the scientific guidelines for precautionary measures (eg, social distancing, wearing face masks, frequent 156 handwashing rituals [excellent hygienic measures] and wearing gloves if necessary). I must 157 voice a word of caution. It is unfortunate and regrettable that national and international politics 158 are involved in the endeavor ahead of us. A healthy competition is, of course, good for all. There 159 is, however, no room for personal or political advantages in our quest for scientific progress in 160 our understanding of the pathogenesis, the natural evolution of the clinical picture, 161 epidemiological pathway as well as finding an effective vaccine and therapy for COVID- 19. 162 Mankind is under attack by an invisible calamitous enemy. Therefore, united, we must follow a 163 course of action which requires collaboration and cooperation. We must destroy the fangs of this Influenza cataclysm, 1918: Perspective Defining the epidemiology of COVID-19-Studies 183 Public health intervention for COVID-19: Emerging evidence 185 and implications for an evolving public health crisis Association of public health interventions with the 187 epidemiology of the COVID-19 outbreak in Wuhan, China A novel coronavirus from patients with pneumonia in 189 Clinical features of patients infected with 2019 novel 191 coronavirus in Wuhan, China Epidemiological and clinical characteristics of 99 cases 193 of 2019 Novel Coronavirus pneumonia in Wuhan, China: a descriptive study First case of 2019 Novel Coronavirus in the 196 United States First 12 patients with coronavirus disease 2019 198 (COVID-19) in the United States COVID-19 in critically ill patients in the 200 Seattle region-case series The COVID-19 pandemic in the US. A clinical update Baseline characteristics and outcome of 1591 204 patients infected with SARS-COV-2 admitted to ICUs of the Lombardy region A man with COVID-19 and acute kidney injury thrombosis, and angiogenesis in COVID-19 Autopsy findings and venous thromboembolism in 211 patients with COVID-19 Large vessel stroke as a presenting feature of COVID-19 213 in the young The immediate impact of the 2019 novel coronavirus 215 Survey of insomnia and related social, psychological factors among 217 medical staff involved with the 2019 novel coronavirus disease outbreak The acute effects of the COVID-19 pandemic on insomnia and 220 psychological symptoms. An Editorial COVID-19 and Angiotensin-Converting Enzyme inhibitors and 222 Angiotensin Receptor Blockers. What is the evidence? Neurological manifestations of hospitalized patients with 224 coronavirus disease-2019 in The neuroinvasive potential of SARS-COV2 may be at least 227 partially responsible for the respiratory failure of COVID-19 patients. Review